<DOC>
	<DOCNO>NCT01283048</DOCNO>
	<brief_summary>BKM-120 drug may slow growth cancer cell . This drug use laboratory experiment information research study suggest drug may help slow growth renal cancer cell . In research study , investigator test safety BKM-120 different dose level . The investigator also study well tolerate BKM-120 , effective BKM-120 treatment kidney cancer .</brief_summary>
	<brief_title>Bevacizumab BKM-120 Patients With Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description>Subjects receive intravenous infusion Avastin Day 1 Day 15 month ( cycle ) . Subjects take daily oral dose BKM-120 dose level assign . Subjects clinic visit weekly Cycle 1 Day 1 Day 15 cycle blood test physical exam .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Metastatic RCC clear cell component papillary RCC Life expectancy &gt; 12 week Must fail least 1 prior antiVEGF systemic therapy metastatic RCC Prior treatment P13K inhibitor bevacizumab Untreated brain metastasis Acute chronic liver pancreatic disease Major mood disorder Concurrent severe and/or uncontrolled medical condition Diabetes mellitus GI disease Currently take therapeutic dos warfarin sodium coumadinderivative anticoagulant Pregnant breastfeeding HIV positive History another malignancy within 3 year except cure basal cell carcinoma skin excise situ carcinoma cervix Uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Kidney Cancer</keyword>
	<keyword>Avastin</keyword>
</DOC>